Vaccine News and Research

RSS

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.

CAR T cells produced in vivo using modified mRNA treat cardiac injury

A new study by researchers from the University of Pennsylvania shows that experimental immunotherapy can temporarily reprogram the immune cells of patients.

10 Jan 2022

Breakthrough infections enhance immune response to COVID-19 variants

Breakthrough infections greatly enhance immune response to variants of the virus that causes COVID-19, according to a newly published study from Oregon Health & Science University.

17 Dec 2021

Novel peptide vaccine alleviates conditions of dyslipidemia

Professor Yuichi Oike and his group of researchers recently produced a peptide vaccine that mitigates conditions of dyslipidemia.

17 Dec 2021

What Role do Genes Play in the Development of Antibodies?

In this interview, we speak to researchers from the University of Toronto about their latest research that investigated the role genes play in the development of antibodies.

From University of Toronto 16 Dec 2021

Driving up the immune response at tumor site may help boost immunotherapy

Driving up the immune response at the site of a cancer tumor with nanotechnology may help enhance immunotherapy treatments in advanced stages of the disease, new research in mice suggests.

15 Dec 2021

Infant's immune system may be better than the adult immune system

As any parent knows, infants are prone to getting respiratory infections. But a new study shows that the infant immune system is stronger than most people think and beats the adult immune system at fighting off new pathogens.

13 Dec 2021

Multiple exposure enhances antibody efficacy against COVID-19 variants

Antibodies produced by the immune system against the SARS-CoV-2 spike protein help pinpoint and avoid future infections.

13 Dec 2021

Scientists unravel the structure of octopus-like Lassa viral polymerase

Endemic in Western African countries, Lassa virus is transmitted to humans through food or household items that are contaminated with the urine or faeces of Mastomys rats.

7 Dec 2021

Duke engineers develop a rapid test to identify antibody effectiveness against COVID-19 variants

Biomedical engineers at Duke University have devised a test to quickly and easily assess how well a person's neutralizing antibodies fight infection from multiple variants of COVID-19 such as Delta and the newly discovered Omicron variant.

6 Dec 2021

New nanoparticle adjuvant could lead to more powerful vaccines

A common strategy to make vaccines more powerful is to deliver them along with an adjuvant -; a compound that stimulates the immune system to produce a stronger response.

6 Dec 2021

Study identifies genes that protect ovarian cancer from antitumor immunity

Immunotherapies are exhibiting better clinical benefit in the treatment of numerous cancers, particularly when used along with chemotherapy.

2 Dec 2021

Nanoparticles mimicking flu viruses to deliver large biological drug molecules

Nanoengineers from the University of California San Diego recently created a new and potentially efficient means to deliver messenger RNA (mRNA) into cells.

2 Dec 2021

Anti-idiotype antibodies may explain the long-term effects of COVID-19

With around 256 million cases and more than 5 million deaths worldwide, the COVID-19 pandemic has challenged scientists and those in the medical field. Researchers are working to find effective vaccines and therapies, as well as understand the long-term effects of the infection.

From The University of California, Davis 26 Nov 2021

Covid-19 vaccine-elicited immune cells persist six months after vaccination, study shows

A recent study by Johns Hopkins Medicine researchers provides evidence that CD4+ T lymphocytes — immune system cells also known as helper T cells — produced by people who received either of the two available messenger RNA (mRNA) vaccines for COVID-19 persist six months after vaccination at only slightly reduced levels from two weeks after vaccination and are at significantly higher levels than for those who are unvaccinated.

17 Nov 2021

Researchers test a neoantigen-specific transgenic immune cell therapy for malignant gliomas

Doctors and scientists from the German Cancer Research Center (DKFZ) and from Heidelberg University's Medical Faculty Mannheim have successfully tested a neoantigen-specific transgenic immune cell therapy for malignant brain tumors for the first time using an experimental model in mice.

16 Nov 2021